- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cytogen reports on Quadramet status
Radiopharmaceutical firm Cytogen announced this month that it is in late-stage negotiations with potential marketing partners for Quadramet, the company’s bone cancer palliative agent. Cytogen is working with former marketing partner Du Pont
Radiopharmaceutical firm Cytogen announced this month that it is in late-stage negotiations with potential marketing partners for Quadramet, the companys bone cancer palliative agent. Cytogen is working with former marketing partner Du Pont Pharmaceuticals to expedite the changeover, according to the company. North Billerica, MA-based Du Pont will continue to manufacture Quadramet.
The two companies initiated an interim agreement June 2 in which they determined that Du Pont would identify marketing partner candidates for Cytogen (SCAN Special Report 6/98). The agreement has been extended through the end of this month, pending the final selection of a new partner and the completion of Cytogens marketing arrangements with Du Pont. Cytogen has taken over the identification and selection of candidates as the process continues.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
